Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMASH: SGLT2 Inhibitors and Metformin in NAFLD
NCT02696941Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Feb 2016
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dapagliflozin in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by University of Oxford. Primary endpoint: Hepatic steatosis at 3 months. Started Feb 2016; status: completed.
02
Drugs
dapagliflozin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02696941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02696941.